These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26041444)

  • 1. Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Am J Physiol Renal Physiol; 2015 Sep; 309(5):F447-55. PubMed ID: 26041444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.
    Awad AS; You H; Gao T; Gvritishvili A; Cooper TK; Tombran-Tink J
    PLoS One; 2015; 10(7):e0133777. PubMed ID: 26207369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Kidney Int; 2013 Dec; 84(6):1189-97. PubMed ID: 23760286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginase-2 mediates diabetic renal injury.
    Morris SM; Gao T; Cooper TK; Kepka-Lenhart D; Awad AS
    Diabetes; 2011 Nov; 60(11):3015-22. PubMed ID: 21926276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in
    Tesch GH; Pullen N; Jesson MI; Schlerman FJ; Nikolic-Paterson DJ
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1439-F1449. PubMed ID: 31566438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of imidapril and captopril on streptozotocin-induced diabetic nephropathy in mice.
    Katoh M; Ohmachi Y; Kurosawa Y; Yoneda H; Tanaka N; Narita H
    Eur J Pharmacol; 2000 Jun; 398(3):381-7. PubMed ID: 10862828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
    Zhang MZ; Wang S; Yang S; Yang H; Fan X; Takahashi T; Harris RC
    Am J Physiol Renal Physiol; 2012 Feb; 302(4):F433-8. PubMed ID: 22114203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.
    Onozato ML; Tojo A; Goto A; Fujita T; Wilcox CS
    Kidney Int; 2002 Jan; 61(1):186-94. PubMed ID: 11786100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct roles of arginases 1 and 2 in diabetic nephropathy.
    Morris SM; You H; Gao T; Vacher J; Cooper TK; Awad AS
    Am J Physiol Renal Physiol; 2017 Oct; 313(4):F899-F905. PubMed ID: 28446459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic nephropathy is resistant to oral L-arginine or L-citrulline supplementation.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Am J Physiol Renal Physiol; 2014 Dec; 307(11):F1292-301. PubMed ID: 25320354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
    Zheng F; Zeng YJ; Plati AR; Elliot SJ; Berho M; Potier M; Striker LJ; Striker GE
    Kidney Int; 2006 Aug; 70(3):507-14. PubMed ID: 16775596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of UP269-6, a new angiotensin II receptor antagonist, and captopril on the progression of rat diabetic nephropathy.
    Villa E; Rábano A; Cazes M; Cloarec A; Ruilope LM; García-Robles R
    Am J Hypertens; 1997 Mar; 10(3):275-81. PubMed ID: 9056684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enalapril treatment increases T cell number and promotes polarization towards M1-like macrophages locally in diabetic nephropathy.
    Cucak H; Nielsen Fink L; Højgaard Pedersen M; Rosendahl A
    Int Immunopharmacol; 2015 Mar; 25(1):30-42. PubMed ID: 25598292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats.
    Pechanova O; Matuskova J; Capikova D; Jendekova L; Paulis L; Simko F
    Kidney Int; 2006 Jul; 70(1):170-6. PubMed ID: 16710350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. l-Homoarginine supplementation prevents diabetic kidney damage.
    Wetzel MD; Gao T; Venkatachalam M; Morris SM; Awad AS
    Physiol Rep; 2019 Sep; 7(18):e14235. PubMed ID: 31552707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors in diabetic nephropathy.
    Melchior WR; Bindlish V; Jaber LA
    Ann Pharmacother; 1993 Mar; 27(3):344-50. PubMed ID: 8384031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice.
    Yotsumoto T; Naitoh T; Shikada K; Tanaka S
    Jpn J Pharmacol; 1997 Sep; 75(1):59-64. PubMed ID: 9334886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients.
    Parving HH; Hommel E; Jensen BR; Hansen HP
    Kidney Int; 2001 Jul; 60(1):228-34. PubMed ID: 11422755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
    Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
    Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelial nitric oxide synthase gene polymorphisms and renal responsiveness to RAS inhibition therapy in type 2 diabetic Asian Indians.
    Cheema BS; Kohli HS; Sharma R; Bhansali A; Khullar M
    Diabetes Res Clin Pract; 2013 Mar; 99(3):335-42. PubMed ID: 23260854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.